Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Name: Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
Author: Basch, Ethan M

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. — المؤلف: Basch, Ethan M — European urology 20200723

المؤلف: Basch, Ethan M
النشر: European urology 20200723
الوصف: 929-937 p.
الموضوعات: Aged؛ Analgesics؛ Anilides؛ Bone Neoplasms؛ Cancer Pain؛ Double-Blind Method؛ Drug Combinations؛ Humans